Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: P01BF05

Eurartesim(piperaquine tetraphosphate;artenimol)

Malaria

Marketing Authorisation Holder: Alfasigma S.p.A.

EMA Authorisation: 27/10/2011

INN: piperaquine tetraphosphate;artenimol

Indication

Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial agents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Eurartesim — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.